- 客服:
- 电话: 13061953619
- 微信:
ERK-IN-1(化合物 B)是一种可口服的 ERK1 和 ERK2 抑制剂,用于治疗以激活 MAPK 通路突变为特征的增殖性疾病。该活性尤其与 KRAS 突变 NSCLC、BRAF 突变 NSCLC、KRAS 突变胰腺癌、KRAS 突变结直肠癌 (CRC) 和 KRAS 突变卵巢癌的治疗有关。 ERK-IN-1 hydrochloride 也可以抑制 RAF。
ERK-IN-1 (compound B) is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1].
ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice[1].|| Animal Model:|Calu-6 NSCLC xenograft tumor models in mice[1].|Dosage:|50, 75 mg/kg.|Administration:|Orally either daily (qd) or every other day (q2d) for 27 days.|Result:|Significantly reduced the tumor volume.
[1]. WO2018051306A1.
动态评分
0.0